Psychosis After Switch in Opioid Maintenance Agonist and Risperidone-Induced Pisa Syndrome: Two Critical Incidents in Dual Diagnosis Treatment

References

• Adair, J. C., & Gilmore, R. L. (1994). Meperidine neurotoxicity after organ transplantation. Journal of Toxicology Clinical Toxicology, 32(3), 325–328.
   PubMed Web of Science ®Google Scholar
• Ansermot, N., Albayrak, O., Schlapfer, J., Crettol, S., Croquette-Krokar, M., Bourquin, M., Eap, C. B. (2010). Substitution of (r, s)-methadone by (r)-methadone: Impact on QTc interval. Archives of Internal Medicine, 170(6), 529–536. doi:10.1001/archinternmed.2010.26
   PubMedGoogle Scholar
• Arora, M., Praharaj, S. K., & Sarkar, S. (2006). Clozapine effective in olanzapine-induced Pisa syndrome. Annals of Pharmacotherapy, 40(12), 2273–2275. doi:10.1345/aph.1H325
   PubMed Web of Science ®Google Scholar
• Arzneimittel-Kompendium. (2014). Sevre-Long. June 17. Retrieved from http://compendium.ch/mpro/mnr/7170/html/de
   Google Scholar
• Beck, T., Haasen, C., Verthein, U., Walcher, S., Schuler, C., Backmund, M., & Reimer, J. (2014). Maintenance treatment for opioid dependence with slow-release oral morphine: A randomized cross-over, non-inferiority study versus methadone. Addiction, 109(4), 617–626. doi:10.1111/add.12440
   PubMed Web of Science ®Google Scholar
• Berg, D., Becker, G., Naumann, M., & Reiners, K. (2001). Morphine in tardive and idiopathic dystonia (short communication). Journal of Neural Transmission, 108(8–9), 1035–1041. doi:10.1007/s007020170022
   PubMed Web of Science ®Google Scholar
• Berken, G. H., Stone, M. M., & Stone, S. K. (1978). Methadone in schizophrenic rage: A case study. American Journal of Psychiatry, 135(2), 248–249. doi:10.1176/ajp.135.2.248
   PubMed Web of Science ®Google Scholar
• Bhidayasiri, R., Fahn, S., Weiner, W. J., Gronseth, G. S., Sullivan, K. L., & Zesiewicz, T. A. (2013). Evidence-based guideline: Treatment of tardive syndromes: Report of the guideline development subcommittee of the American Academy of Neurology. Neurology, 81(5), 463–469. doi:10.1212/WNL.0b013e31829d86b6
   PubMed Web of Science ®Google Scholar
• Boettcher, C., Fellermeier, M., Boettcher, C., Drager, B., & Zenk, M. H. (2005). How human neuroblastoma cells make morphine. Proceedings of the National Academy of Sciences, 102(24), 8495–8500. doi:10.1073/pnas.0503244102
   PubMed Web of Science ®Google Scholar
• Borentain, S., Millet, B., & Olie, J. P. (2002). Cardiac risk at the onset of treatment in patients treated with benzodiazepines and clozapine. European Psychiatry, 17(7), 419–420.
   PubMed Web of Science ®Google Scholar
• Brizer, D. A., Hartman, N., Sweeney, J., & Millman, R. B. (1985). Effect of methadone plus neuroleptics on treatment-resistant chronic paranoid schizophrenia. American Journal of Psychiatry, 142(9), 1106–1107. doi:10.1176/ajp.142.9.1106
   PubMed Web of Science ®Google Scholar
• Chung, A. K., & Chua, S. E. (2011). Effects on prolongation of Bazett's corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: A meta-analysis. Journal of Psychopharmacology, 25(5), 646–666. doi:10.1177/0269881110376685
   PubMed Web of Science ®Google Scholar
• Cobo, J., Ramos, M. M., Pelaez, T., Garcia, G., & Marsal, F. (2006). Psychosis related to methadone withdrawal. Acta Neuropsychiatrica, 18(1). doi:10.1111/j.0924-2708.2006.00109.x
   PubMed Web of Science ®Google Scholar
• Cordeiro, Q., Zung, S., & Vallada, H. (2008). Pisa syndrome induced by rapid increase and high dosage of risperidone. Arquivos de Neuro-Psiquiatria, 66(4), 896–897.
   PubMed Web of Science ®Google Scholar
• Davis, G. C., Bunney, W. E., Jr., DeFraites, E. G., Kleinman, J. E., van Kammen, D. P., Post, R. M., & Wyatt, R. J. (1977). Intravenous naloxone administration in schizophrenia and affective illness. Science, 197(4298), 74–77.
   PubMed Web of Science ®Google Scholar
• Deik, A., Saunders-Pullman, R., & Luciano, M. S. (2012). Substance abuse and movement disorders: Complex interactions and comorbidities. Current Drug Abuse Reviews, 5(3), 243–253.
   PubMedGoogle Scholar
• Ekbom, K., Lindholm, H., & Ljungberg, L. (1972). New dystonic syndrome associated with butyrophenone therapy. Zeitschrift für Neurologie, 202(2), 94–103.
   PubMedGoogle Scholar
• EMCDDA. (2014). European drug report 2014: Trends and developments. Retrieved from http://www.emcdda.europa.eu/attachements.cfm/att_228272_EN_TDAT14001ENN.pdf
   Google Scholar
• Feinberg, D. T., & Hartmann, N. (1991). Methadone and schizophrenia. American Journal of Psychiatry, 148(12), 1750–1751.
   PubMed Web of Science ®Google Scholar
• Gaspari, J., Swift, R., Kleber, H., Riordan, C., & Santangelo, S. (1985). Prevalence of movement disorder in a methadone-maintained population. The Journal of Nervous and Mental Disease, 173(6), 373–376.
   PubMed Web of Science ®Google Scholar
• Gold, M. S., Donabedian, R. K., Dillard, M., Jr., Slobetz, F. W., Riordan, C. E., & Kleber, H. D. (1977). Antipsychotic effect of opiate agonists. The Lancet, 2(8034), 398–399.
   PubMed Web of Science ®Google Scholar
• Gold, M. S., Redmond, D. E., Jr., & Donabedian, R. K. (1978). Prolactin secretion, a measurable central effect of opiate-receptor antagonists. The Lancet, 1(8059), 323–324.
   PubMed Web of Science ®Google Scholar
• Hammig, R., Kohler, W., Bonorden-Kleij, K., Weber, B., Lebentrau, K., Berthel, T., & Ruckes, C. (2014). Safety and tolerability of slow-release oral morphine versus methadone in the treatment of opioid dependence. Journal of Substance Abuse Treatment, 47(4), 275–281. doi:10.1016/j.jsat.2014.05.012
   PubMed Web of Science ®Google Scholar
• Harada, K., Sasaki, N., Ikeda, H., Nakano, N., Ozawa, H., & Saito, T. (2002). Risperidone-induced Pisa syndrome. Journal of Clinical Psychiatry, 63(2), 166.
   PubMed Web of Science ®Google Scholar
• Heales, S., Crawley, F., & Rudge, P. (2004). Reversible parkinsonism following heroin pyrolysate inhalation is associated with tetrahydrobiopterin deficiency. Movement Disorders, 19(10), 1248–1251. doi:10.1002/mds.20158
   PubMed Web of Science ®Google Scholar
• Huvent-Grelle, D., Boulanger, E., & Puisieux, F. (2014). Relationship between Pisa syndrome and cholinesterase inhibitor use for elderly adults with Alzheimer's disease. Journal of the American Geriatrics Society, 62(12), 2450–2453. doi:10.1111/jgs.13168
   PubMed Web of Science ®Google Scholar
• Iuppa, C. A., & Diefenderfer, L. A. (2013). Risperidone-induced Pisa syndrome in MS: Resolution with lurasidone and recurrence with Chlorpromazine. Annals of Pharmacotherapy, 47(9), 1223–1228. doi:10.1177/1060028013503132
   PubMed Web of Science ®Google Scholar
• Jagadheesan, K., & Nizamie, S. H. (2002). Risperidone-induced Pisa syndrome. Australian New Zealand Journal Psychiatry, 36(1), 144.
   PubMed Web of Science ®Google Scholar
• Janowsky, D. S., Segal, D. S., Bloom, F., Abrams, A., & Guillemin, R. (1977). Lack of effect on naloxone on schizophrenic symptoms. American Journal of Psychiatry, 134(8), 926–927. doi:10.1176/ajp.134.8.926
   PubMed Web of Science ®Google Scholar
• Judd, L. L., Risch, S. C., Segal, D. S., Janowsky, D. S., & Huey, L. Y. (1983). Behavioral and neuroendocrine effects of opioid receptor agonists in psychopathologic states. Psychiatric Clinics of North America, 6(3), 393–402.
   PubMed Web of Science ®Google Scholar
• Kanouse, A. B., & Compton, P. (2015). The epidemic of prescription opioid abuse, the subsequent rising prevalence of heroin use, and the federal response. Journal of Pain & Palliative Care Pharmacotherapy, 29(2), 102–114. doi:10.3109/15360288.2015.1037521
   PubMedGoogle Scholar
• Karila, L., Berlin, I., Benyamina, A., & Reynaud, M. (2008). Psychotic symptoms following buprenorphine withdrawal. American Journal of Psychiatry, 165(3), 400–401. doi:10.1176/appi.ajp.2007.07071103
   PubMed Web of Science ®Google Scholar
• Kaufmann, A., Boesch, S., Fleischhacker, W. W., & Hofer, A. (2012). Management of a risperidone-induced tardive Pisa syndrome: A case report. Journal of Clinical Psychopharmacology, 32(3), 418–420. doi:10.1097/JCP.0b013e318253e067
   PubMed Web of Science ®Google Scholar
• Kern, A. M., Akerman, S. C., & Nordstrom, B. R. (2014). Opiate dependence in schizophrenia: Case presentation and literature review. Journal of Dual Diagnosis, 10(1), 52–57. doi:10.1080/15504263.2013.867199
   PubMed Web of Science ®Google Scholar
• Koprich, J. B., Fox, S. H., Johnston, T. H., Goodman, A., Le Bourdonnec, B., Dolle, R. E., & Brotchie, J. M. (2011). The selective mu-opioid receptor antagonist adl5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in mptp-lesioned macaque model of Parkinson's disease. Movement Disorders, 26(7), 1225–1233. doi:10.1002/mds.23631
   PubMed Web of Science ®Google Scholar
• Krantz, M. J. (2008). Heterogeneous impact of methadone on the QTc interval: What are the practical implications? Journal of Addictive Diseases, 27(4), 5–9. doi:10.1080/10550880802324317
   PubMed Web of Science ®Google Scholar
• Kream, R. M., Kuzelova, H., Kralickova, M., Ptacek, R., & Stefano, G. B. (2012). Co-morbidity and self medication in schizophrenia: Involvement of endogenous morphine signaling mechanisms. Current Drug Targets, 13(11), 1454–1457.
   PubMed Web of Science ®Google Scholar
• Kream, R. M., & Stefano, G. B. (2006). De novo biosynthesis of morphine in animal cells: An evidence-based model. Medical Science Monitor, 12(10), 207–219.
   Web of Science ®Google Scholar
• Kriegstein, A. R., Shungu, D. C., Millar, W. S., Armitage, B. A., Brust, J. C., Chillrud, S., & Lynch, T. (1999). Leukoencephalopathy and raised brain lactate from heroin vapor inhalation (“chasing the dragon”). Neurology, 53(8), 1765–1773.
   PubMed Web of Science ®Google Scholar
• Lauterbach, E. C. (1999). Hiccup and apparent myoclonus after hydrocodone: Review of the opiate-related hiccup and myoclonus literature. Clinical Neuropharmacology, 22(2), 87–92.
   PubMed Web of Science ®Google Scholar
• Leucht, S., Cipriani, A., Spineli, L., Mavridis, D., Orey, D., Richter, F., & Davis, J. M. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. The Lancet, 382(9896), 951–962. doi:10.1016/s0140-6736(13)60733-3
   PubMed Web of Science ®Google Scholar
• Levinson, I., Galynker, I. I., & Rosenthal, R. N. (1995). Methadone withdrawal psychosis. Journal of Clinical Psychiatry, 56(2), 73–76.
   PubMed Web of Science ®Google Scholar
• Lindstrom, L. H., Widerlov, E., Gunne, L. M., Wahlstrom, A., & Terenius, L. (1978). Endorphins in human cerebrospinal fluid: clinical correlations to some psychotic states. Acta Psychiatrica Scandinavica, 57(2), 153–164.
   PubMed Web of Science ®Google Scholar
• Magnan, J., Paterson, S. J., Tavani, A., & Kosterlitz, H. W. (1982). The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties. Naunyn-Schmiedeberg's Archives of Pharmacology, 319(3), 197–205.
   PubMed Web of Science ®Google Scholar
• Maremmani, A. G., Dell'Osso, L., Pacini, M., Popovic, D., Rovai, L., Torrens, M., & Maremmani, I. (2011). Dual diagnosis and chronology of illness in treatment-seeking Italian patients dependent on heroin. Journal of Addictive Diseases, 30(2), 123–135. doi:10.1080/10550887.2011.554779
   PubMed Web of Science ®Google Scholar
• McKenna, G. J. (1982). Methadone and opiate drugs: Psychotropic effect and self-medication. Annals of the New York Academy of Sciences, 398, 44–55.
   PubMed Web of Science ®Google Scholar
• Mehta, A., Bot, G., Reisine, T., & Chesselet, M. F. (2001). Endomorphin-1: Induction of motor behavior and lack of receptor desensitization. Journal of Neuroscience, 21(12), 4436–4442.
   PubMed Web of Science ®Google Scholar
• Mendez Guerrero, A., Llamas, S., Murcia, F. J., & Ruiz, J. (2013). Acute Pisa syndrome after administration of a single dose of mirtazapine. Clinical Neuropharmacology, 36(4), 133–134. doi:10.1097/WNF.0b013e318297593d
   PubMed Web of Science ®Google Scholar
• Mielke, D. H., & Gallant, D. M. (1977). An oral opiate antagonist in chronic schizophrenia: A pilot study. American Journal of Psychiatry, 134(12), 1430–1431. doi:10.1176/ajp.134.12.1430
   PubMed Web of Science ®Google Scholar
• Nishimura, K., Mikami, Y., Tsuchibuchi, S., & Horikawa, N. (2007). Pisa syndrome resolved after switching to olanzapine. The Journal of Neuropsychiatry and Clinical Neurosciences, 19(2), 202–203. doi:10.1176/jnp.2007.19.2.202
   PubMed Web of Science ®Google Scholar
• Pacini, M., & Maremmani, I. (2005). Methadone reduces the need for antipsychotic and antimanic agents in heroin addicts hospitalized for manic and/or acute psychotic episodes. Heroin Addiction And Related Clinical Problems, 7(4), 43–48.
   Google Scholar
• Potvin, S., Pampoulova, T., Mancini-Marie, A., Lipp, O., Bouchard, R. H., & Stip, E. (2006). Increased extrapyramidal symptoms in patients with schizophrenia and a comorbid substance use disorder. Journal of Neurology, Neurosurgery & Psychiatry, 77(6), 796–798. doi:10.1136/jnnp.2005.079228
   PubMed Web of Science ®Google Scholar
• Quednow, B. B., Csomor, P. A., Chmiel, J., Beck, T., & Vollenweider, F. X. (2008). Sensorimotor gating and attentional set-shifting are improved by the mu-opioid receptor agonist morphine in healthy human volunteers. International Journal of Neuropsychopharmacology, 11(5), 655–669. doi:10.1017/s1461145707008322
   PubMed Web of Science ®Google Scholar
• Ranganathan, M., Schnakenberg, A., Skosnik, P. D., Cohen, B. M., Pittman, B., Sewell, R. A., & D'Souza, D. C. (2012). Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the kappa opioid agonist salvinorin A in humans. Biological Psychiatry, 72(10), 871–879. doi:10.1016/j.biopsych.2012.06.012
   PubMed Web of Science ®Google Scholar
• Regier, D. A., Farmer, M. E., Rae, D. S., Locke, B. Z., Keith, S. J., Judd, L. L., & Goodwin, F. K. (1990). Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA, 264(19), 2511–2518.
   PubMed Web of Science ®Google Scholar
• Roy, A. K., McCarthy, C., Kiernan, G., McGorrian, C., Keenan, E., Mahon, N. G., & Sweeney, B. (2012). Increased incidence of QT interval prolongation in a population receiving lower doses of methadone maintenance therapy. Addiction, 107(6), 1132–1139. doi:10.1111/j.1360-0443.2011.03767.x
   PubMed Web of Science ®Google Scholar
• Sandyk, R. (1985). The endogenous opioid system in neurological disorders of the basal ganglia. Life Sciences, 37(18), 1655–1663.
   PubMed Web of Science ®Google Scholar
• Sandyk, R., & Gillman, M. A. (1986). The opioid system in the restless legs and nocturnal myoclonus syndromes. Sleep, 9(2), 370–371.
   PubMed Web of Science ®Google Scholar
• Schmidt, L. M., Hesse, M., & Lykke, J. (2011). The impact of substance use disorders on the course of schizophrenia—a 15-year follow-up study: Dual diagnosis over 15 years. Schizophrenia Research, 130(1–3), 228–233. doi:10.1016/j.schres.2011.04.011
   PubMed Web of Science ®Google Scholar
• Shreeram, S. S., McDonald, T., & Dennison, S. (2001). Psychosis after ultrarapid opiate detoxification. American Journal of Psychiatry, 158(6), 970. doi:10.1176/appi.ajp.158.6.970
   PubMed Web of Science ®Google Scholar
• Simpson, G. M., Branchey, L. H., & Lee, J. H. (1977). A trial of naltrexone in chronic schizophrenia. Current Therapeutic Research, 22, 909–913.
   Web of Science ®Google Scholar
• SSAM. (2012). Medizinische Empfehlungen für substitutionsgestützte Behandlungen (SGB) bei Opioidabhängigkeit [Medical recommendations for substitution-assisted treatment of opioid dependence]. Retrieved from http://www.ssam.ch/SSAM/sites/default/files/Empfehlungen%20SGB_2012_FINAL_26%2011%202012.pdf
   Google Scholar
• Stefano, G. B., Kralickova, M., Ptacek, R., Kuzelova, H., Esch, T., & Kream, R. M. (2012). Low dose morphine adjuvant therapy for enhanced efficacy of antipsychotic drug action: Potential involvement of endogenous morphine in the pathophysiology of schizophrenia. Medical Science Monitor, 18(7), HY23–HY26.
   PubMed Web of Science ®Google Scholar
• Stubner, S., Padberg, F., Grohmann, R., Hampel, H., Hollweg, M., Hippius, H., & Ruther, E. (2000). Pisa syndrome (pleurothotonus): Report of a multicenter drug safety surveillance project. Journal of Clinical Psychiatry, 61(8), 569–574.
   PubMedGoogle Scholar
• Suzuki, T., Hori, T., Baba, A., Abe, S., Shiraishi, H., Moroji, T., & Piletz, J. E. (1999). Effectiveness of anticholinergics and neuroleptic dose reduction on neuroleptic-induced pleurothotonus (the Pisa syndrome). Journal of Clinical Psychopharmacology, 19(3), 277–280.
   PubMed Web of Science ®Google Scholar
• Suzuki, T., Kurita, H., Hori, T., Sasaki, M., Baba, A., Shiraishi, H., & Piletz, J. E. (1997). The Pisa syndrome (pleurothotonus) during antidepressant therapy. Biological Psychiatry, 41(2), 234–236. doi:10.1016/s0006-3223(96)00405-2
   PubMed Web of Science ®Google Scholar
• Suzuki, T., & Matsuzaka, H. (2002). Drug-induced Pisa syndrome (pleurothotonus): Epidemiology and management. CNS Drugs, 16(3), 165–174.
   PubMed Web of Science ®Google Scholar
• Tejeda, H. A., Shippenberg, T. S., & Henriksson, R. (2012). The dynorphin/kappa-opioid receptor system and its role in psychiatric disorders. Cellular and Molecular Life Sciences, 69(6), 857–896. doi:10.1007/s00018-011-0844-x
   PubMed Web of Science ®Google Scholar
• Teng, P. R., & Lai, T. J. (2013). Paliperidone-related Pisa syndrome. Journal of Clinical Psychopharmacology, 33(1), 129–131. doi:10.1097/01.jcp.0000426181.89572.18
   PubMed Web of Science ®Google Scholar
• Torrens, M., Rossi, P. C., Martinez-Riera, R., Martinez-Sanvisens, D., & Bulbena, A. (2012). Psychiatric co-morbidity and substance use disorders: Treatment in parallel systems or in one integrated system? Substance Use & Misuse, 47(8–9), 1005–1014. doi:10.3109/10826084.2012.663296
   PubMed Web of Science ®Google Scholar
• Verebey, K., Volavka, J., & Clouet, D. (1978). Endorphins in psychiatry: An overview and a hypothesis. Archives of General Psychiatry, 35(7), 877–888.
   PubMed Web of Science ®Google Scholar
• Verthein, U., Beck, T., Haasen, C., & Reimer, J. (2015). Mental symptoms and drug use in maintenance treatment with slow-release oral morphine compared to methadone: Results of a randomized crossover study. European Addiction Research, 21(2), 97–104. doi:10.1159/000368572
   PubMed Web of Science ®Google Scholar
• Villarejo, A., Camacho, A., Garcia-Ramos, R., Moreno, T., Penas, M., Juntas, R., & Ruiz, J. (2003). Cholinergic-dopaminergic imbalance in Pisa syndrome. Clinical Neuropharmacology, 26(3), 119–121.
   PubMed Web of Science ®Google Scholar
• Volavka, J., Mallya, A., Baig, S., & Perez-Cruet, J. (1977). Naloxone in chronic schizophrenia. Science, 196(4295), 1227–1228.
   PubMed Web of Science ®Google Scholar
• Weibel, S., Mallaret, M., Bennouna-Greene, M., & Bertschy, G. (2012). A case of acute psychosis after buprenorphine withdrawal: Abrupt versus progressive discontinuation could make a difference. Journal of Clinical Psychiatry, 73(6), e756. doi:10.4088/JCP.11cr07608
   Google Scholar
• Westermeyer, J. (2006). Comorbid schizophrenia and substance abuse: A review of epidemiology and course. American Journal on Addictions, 15(5), 345–355. doi:10.1080/10550490600860114
   PubMed Web of Science ®Google Scholar
• White, K. L., & Roth, B. L. (2012). Psychotomimetic effects of kappa opioid receptor agonists. Biological Psychiatry, 72(10), 797–798. doi:10.1016/j.biopsych.2012.08.014
   PubMed Web of Science ®Google Scholar
• Williams, A. R., & Bisaga, A. (2016). From AIDS to opioids—how to combat an epidemic. New England Journal of Medicine, 375(9), 813–815. doi:10.1056/NEJMp1604223
   PubMed Web of Science ®Google Scholar
• World Health Organization, United Nations Office on Drugs and Crime, Joint United Nations Programme on HIV/AIDS. (2004). Substitution maintenance therapy in the management of opioid dependence and HIV/AIDS prevention. WHO/UNODC/UNAIDS position paper. Retrieved from http://www.who.int/substance_abuse/publications/en/PositionPaper_English.pdf
   Google Scholar
• Yassa, R., Nastase, C., Cvejic, J., & Laberge, G. (1991). The Pisa syndrome (or pleurothotonus): Prevalence in a psychogeriatric population. Biological Psychiatry, 29(9), 942–945.
   PubMed Web of Science ®Google Scholar
• Zannas, A. S., Okuno, Y., & Doraiswamy, P. M. (2014). Cholinesterase inhibitors and Pisa syndrome: A pharmacovigilance study. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 34(3), 272–278. doi:10.1002/phar.1359
   Google Scholar
• Zhornitsky, S., Stip, E., Pampoulova, T., Rizkallah, E., Lipp, O., Bentaleb, L. A., & Potvin, S. (2010). Extrapyramidal symptoms in substance abusers with and without schizophrenia and in nonabusing patients with schizophrenia. Movement Disorders, 25(13), 2188–2194. doi:10.1002/mds.23227
   PubMed Web of Science ®Google Scholar
• Zhu, W., Cadet, P., Baggerman, G., Mantione, K. J., & Stefano, G. B. (2005). Human white blood cells synthesize morphine: Cyp2d6 modulation. The Journal of Immunology, 175(11), 7357–7362.
   PubMed Web of Science ®Google Scholar
• Zhu, W., Mantione, K. J., Shen, L., Cadet, P., Esch, T., Goumon, Y., & Stefano, G. B. (2005). Tyrosine and tyramine increase endogenous ganglionic morphine and dopamine levels in vitro and in vivo: Cyp2d6 and tyrosine hydroxylase modulation demonstrates a dopamine coupling. Medical Science Monitor, 11(11), BR397–BR404.
   PubMed Web of Science ®Google Scholar